VVT Med Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	0.08	0.09	0.49	0.04
Revenue Growth (YoY)	-40.31%	-81.91%	1100.00%	-
Cost of Revenue	0.02	0.03	0.12	0.04
Gross Profit	0.05	0.06	0.37	0.01
Selling, General & Admin	2.29	2.2	1.22	1.46
Research & Development	0.52	0.45	0.26	0.33
Other Operating Expenses	-	-	-0.01	-0.04
Operating Expenses	2.81	2.65	1.47	1.75
Operating Income	-2.76	-2.59	-1.1	-1.75
Interest Expense	-0.34	-0.46	-0.4	-0.36
Interest & Investment Income	0.02	0	-	0
Currency Exchange Gain (Loss)	-0.11	-0.11	0.45	-0.16
Other Non Operating Income (Expenses)	-0.83	-0.83	0	0.07
Pretax Income	-4.01	-3.98	-1.04	-2.2
Net Income	-4.01	-3.98	-1.04	-2.2
Net Income to Common	-4.01	-3.98	-1.04	-2.2
Shares Outstanding (Basic)	59	49	27	4
Shares Outstanding (Diluted)	59	49	27	4
Shares Change (YoY)	76.91%	79.50%	526.52%	-
EPS (Basic)	-0.07	-0.08	-0.04	-0.50
EPS (Diluted)	-0.07	-0.08	-0.04	-0.50
Free Cash Flow	-2.9	-3.17	-0.91	-1.4
Free Cash Flow Per Share	-0.05	-0.06	-0.03	-0.32
Gross Margin	68.83%	70.79%	76.02%	12.20%
Operating Margin	-3585.71%	-2904.49%	-222.76%	-4256.10%
Profit Margin	-5207.79%	-4467.42%	-211.38%	-5356.10%
Free Cash Flow Margin	-3768.83%	-3556.18%	-185.16%	-3419.51%
EBITDA	-2.76	-2.58	-1.09	-1.74
EBITDA Margin	-	-	-222.15%	-
D&A For EBITDA	0	0	0	0
EBIT	-2.76	-2.59	-1.1	-1.75
EBIT Margin	-	-	-222.76%	-